Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

The Paradigm Shift in Therapeutic Intervention for ALS: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS

April 3, 2022

CNM-Au8 Data From the RESCUE-ALS Open-Label Extension: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS

April 1, 2022

Clene Could be Big Part of "Momentous Year" for ALS Research

March 30, 2022

CNM-Au8 Shows Effects on Brain Bioenergetic Metabolism, Supports Candidacy in Multiple Sclerosis

February 27, 2022

New Clene CFO to focus on financing runway amid beaten down sector, rising rates

February 14, 2022

Could drinking gold nanoparticles regenerate our nervous system?

February 8, 2022

Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases

January 27, 2022

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved